A comprehensive view of Blood Disorders. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Sustainability & Social Responsibility Market Intelligence Service.
Novartis AG gets positive opinion from CHMP for Fabhalta paroxysmal nocturnal hemoglobinuria treatment for adults; the therapy awaits final European Commission approval in the next two months, potentially becoming Europe's first oral monotherapy for PNH
Published:
March 22, 2024
by dpa-AFX International Compact
|
Boehringer Ingelheim partners with Shanghai RAAS for the development and clinical production of hemophilia drug SR604 injection; the drug has received approval for Phase I clinical trial targeting hemophilia and congenital factor VII deficiency
Published:
March 21, 2024
by Contify Life Science News
|
Janssen Pharmaceutical targets innovative therapies for major diseases, aiming to transform patient care in AMD, multiple myeloma, and lung cancer
Published:
March 19, 2024
by Industry Intelligence Inc.
|
Bristol-Myers Squibb leads hematology innovation and expands neuroscience portfolio while advancing personalized CLL therapeutics
Published:
March 19, 2024
by Industry Intelligence Inc.
|
FDA advisory committee recommends early use of Janssen's new immunotherapy for relapsed/refractory multiple myeloma
Published:
March 16, 2024
by Industry Intelligence Inc.
|
Ask us about our Sustainability & Social Responsibility market view